CClinicalTrials.gg
RecruitingNCT01900821Updated Oct 2, 2025

National Mammography Database

An observational study in Breast Cancer Screening and Diagnosis, sponsored by American College of Radiology. Recruiting at 1 site in United States. Open to participants aged 2 Years to 99 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-10-02.

Sponsored by American College of Radiology · Observational

Study type
Observational
Model
Ecologic or community
Time perspective
Prospective
Enrollment
8,000,000
Ages
2 Years to 99 Years
Sex
All
01

Study summary

The National Mammography Database (NMD) leverages data that radiology practices are already collecting under federal mandate by providing them with comparative information for national and regional benchmarking. Participants receive semi-annual feedback reports that include important benchmark data such as cancer detection rates, positive predictive value rates and recall rates. Participation in the NMD is free to Breast Imaging Center of Excellence (BICOE) facilities.

02

Conditions studied

  • Breast Cancer Screening and Diagnosis

Browse trials for

03

In context

Disease

1,327 studies on the registry are indexed under Disease; 596 are open to participants now.

This study's planned enrollment of 8,000,000 is above the median of 210 across 573 observational studies indexed under Disease.

Browse Disease studies →

Lead sponsor

American College of Radiology is the lead sponsor of 14 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
2 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Women (primarily, but not exclusively), having mammograms at facilities participating in the registry

Inclusion criteria

  • All

Exclusion criteria

Exclusion Criteria:

  • None
05

Study design

Observational model
Ecologic or community
Time perspective
Prospective
Enrollment
8,000,000 participants (estimated)
Target follow-up
1 Year
Patient registry
Yes

Groups and cohorts

  • Women

    All women having mammograms

06

What researchers measure

Primary outcomes

  1. Cancer Detection Rate

    This outcome measure is measured using one year of follow-up after a mammogram is performed on a woman, and is aggregated by interpreting physician. Because the NMD is a registry and screening mammograms are annual exams for most patients, this measure is calculated each year using one year of follow-up.

    Time frame: 1 year

07

Study locations

1 of 1 sites recruiting
  • ACR
    Reston, Virginia 20190, United States
    Recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 2, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01900821
Lead sponsor
American College of Radiology
Responsible party
Sponsor
First posted
Jul 17, 2013
Start date
Jul 2009
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Oct 2, 2025

Study contacts

Mythreyi B Chatfield, PhD
Contact
mchatfield@acr.org
703-715-4394

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion